| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.81 [0.74, 0.89] | | < 1 | | 0% | 6 studies (6/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.69 [0.57, 0.84] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.65 [0.54, 0.78] | | < 1 | | 62% | 5 studies (5/-) | 100.0 % | low | not evaluable | high | important | - |
| DCR | 1.15 [0.79, 1.68] | | > 1 | | 0% | 1 study (1/-) | 76.8 % | NA | not evaluable | | non important | - |
| DOR | 0.41 [0.20, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.96 [1.03, 3.72] | | > 1 | | 86% | 6 studies (6/-) | 98.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.65 [1.48, 4.73] | | < 1 | | 0% | 3 studies (3/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 2.46 [1.59, 3.82] | | < 1 | | 67% | 3 studies (3/-) | 0.0 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.58 [0.89, 2.80] | | < 1 | | 0% | 4 studies (4/-) | 5.7 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 3.05 [0.63, 14.86] | | < 1 | | 87% | 3 studies (3/-) | 8.4 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 3.19 [2.19, 4.65] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.24 [0.85, 1.81] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.26 [0.38, 4.14] | | < 1 | | 94% | 5 studies (5/-) | 35.4 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.66 [0.54, 5.14] | | < 1 | | 95% | 5 studies (5/-) | 18.9 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 3.31 [0.76, 14.36] | | < 1 | | 0% | 4 studies (4/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.62 [0.86, 3.05] | | < 1 | | 36% | 3 studies (3/-) | 6.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.06 [0.87, 4.87] | | < 1 | | 0% | 2 studies (2/-) | 5.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 5.93 [0.30, 118.96] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.08 [0.01, 0.43] | | < 1 | | 0% | 2 studies (2/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.30 [0.50, 3.42] | | < 1 | | 0% | 3 studies (3/-) | 29.4 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 1.64 [0.45, 5.96] | | < 1 | | 0% | 3 studies (3/-) | 22.5 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 2.86 [0.59, 13.95] | | < 1 | | 0% | 3 studies (3/-) | 9.8 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.58 [0.07, 4.55] | | < 1 | | 0% | 3 studies (3/-) | 69.9 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.08 [0.25, 4.71] | | < 1 | | 57% | 4 studies (4/-) | 45.8 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 1.98 [0.25, 15.69] | | < 1 | | 0% | 3 studies (3/-) | 26.0 % | some concern | not evaluable | moderate | non important | - |
| Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.98 [0.02, 49.62] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.48 [0.10, 2.26] | | < 1 | | 57% | 3 studies (3/-) | 82.4 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.85 [0.77, 19.20] | | < 1 | | 0% | 4 studies (4/-) | 5.0 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.71 [0.27, 10.69] | | < 1 | | 0% | 4 studies (4/-) | 28.3 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.43 [0.11, 18.64] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.98 [0.10, 9.42] | | < 1 | | 0% | 3 studies (3/-) | 50.8 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 52.70 [7.19, 385.99] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 32.40 [7.79, 134.72] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.99 [0.64, 1.52] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.38 [0.80, 2.37] | | < 1 | | 0% | 3 studies (3/-) | 12.1 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.61 [0.35, 7.36] | | < 1 | | 0% | 3 studies (3/-) | 27.2 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.18 [0.05, 0.69] | | < 1 | | 0% | 3 studies (3/-) | 99.4 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.08 [0.01, 0.60] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.61 [0.37, 18.36] | | < 1 | | 0% | 3 studies (3/-) | 16.9 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 4.00 [0.65, 24.72] | | < 1 | | 0% | 3 studies (3/-) | 6.9 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 2.75 [0.59, 12.86] | | < 1 | | 0% | 4 studies (4/-) | 10.0 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.22 [0.24, 6.13] | | < 1 | | 0% | 1 study (1/-) | 40.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.05 [0.58, 1.89] | | < 1 | | 0% | 4 studies (4/-) | 44.0 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.33 [0.11, 1.03] | | < 1 | | 0% | 3 studies (3/-) | 97.2 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 1.33 [0.15, 12.01] | | < 1 | | 82% | 2 studies (2/-) | 39.9 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 0.14 [0.02, 0.77] | | < 1 | | 0% | 2 studies (2/-) | 98.8 % | low | not evaluable | high | non important | - |
| Chills AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.99 [0.17, 5.73] | | < 1 | | 0% | 2 studies (2/-) | 50.5 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 2.00 [0.18, 22.13] | | < 1 | | 0% | 2 studies (2/-) | 28.7 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 3.03 [0.17, 53.71] | | < 1 | | 81% | 2 studies (2/-) | 22.7 % | low | not evaluable | high | non important | - |
| Diarrhoea AE (grade 3-4) | 21.14 [1.23, 363.94] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 5.55 [1.41, 21.79] | | < 1 | | 0% | 2 studies (2/-) | 0.7 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 2.86 [1.61, 5.08] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| Headache AE (grade 3-4) | 2.94 [0.58, 14.91] | | < 1 | | 0% | 2 studies (2/-) | 9.7 % | low | not evaluable | high | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 18.42 [5.64, 60.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 34.83 [8.39, 144.67] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.38 [0.67, 2.86] | | < 1 | | 0% | 2 studies (2/-) | 19.0 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.03 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 4.97 [0.58, 42.77] | | < 1 | | 0% | 1 study (1/-) | 7.3 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 7.90 [0.98, 63.82] | | < 1 | | 0% | 2 studies (2/-) | 2.7 % | low | not evaluable | high | non important | - |
| Pyrexia AE (grade 3-4) | 3.79 [0.36, 39.89] | | < 1 | | 0% | 2 studies (2/-) | 13.6 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 6.71 [1.20, 37.51] | | < 1 | | 0% | 2 studies (2/-) | 1.5 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.26] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 1.70 [0.85, 3.42] | | < 1 | | 0% | 2 studies (2/-) | 6.7 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased AE (grade 3-4) | 1.00 [0.14, 7.12] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | some concern | not evaluable | moderate | non important | - |
